Intas Pharmaceuticals under FDA scrutiny over 'cascade of failure' in oversight of GMP documents
Intas Pharmaceuticals is in the FDA’s hot seat after inspectors noted a variety of issues on a recent plant visit, including shredded records that were allegedly found in trash areas, a nearby truck, and hidden under a staircase.
The Ahmedabad, India-based manufacturer received a Form 483 — a document given out when inspectors observe “objectionable” conditions — following a site inspection conducted between late November and early December of last year. Investigators noted a slew of potential issues in the 36-page form, including incomplete lab records and a “cascade of failure” in the quality unit’s oversight of Good Manufacturing Practices (GMP) documents.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.